Literature DB >> 25560576

Taking aim at a dynamic target: Noscapinoids as microtubule-targeted cancer therapeutics.

Manu Lopus1, Pradeep Kumar Naik2.   

Abstract

Noscapine and its synthetic derivatives called noscapinoids have been shown to possess potential anticancer properties. These alkaloids target microtubules and inhibit cell proliferation. Noscapinoids are microtubule poisons that induce minor alterations in the innate dynamic instability of microtubules leading to mitotic arrest and cell death. Over the past decade, a number of noscapine derivatives have been synthesized that, compared to the parent compound, show superior anticancer potential, enhanced tumor specificity and tumor regression, and little or no toxicity to normal tissues. Based on their successive synthetic modifications at different points in the scaffold structure of noscapine, aided by computational design and structure-activity relationship studies, the derivatives of noscapine have been classified into different "generations" based on modifications. Several studies have reported the potential to develop noscapinoids as anticancer drugs. Increasing their tumor specificity - either through antibody conjugation or nanoparticle-based carriers - may facilitate the progression of maytansinoid-based cancer drugs to the clinic.
Copyright © 2014 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.

Entities:  

Keywords:  Anticancer agents; Microtubule; Noscapine; Noscapinoids; Tubulin

Mesh:

Substances:

Year:  2014        PMID: 25560576     DOI: 10.1016/j.pharep.2014.09.003

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  5 in total

Review 1.  The Noscapine Chronicle: A Pharmaco-Historic Biography of the Opiate Alkaloid Family and its Clinical Applications.

Authors:  Padmashree C G Rida; Dillon LiVecche; Angela Ogden; Jun Zhou; Ritu Aneja
Journal:  Med Res Rev       Date:  2015-07-14       Impact factor: 12.944

2.  An Orally Available Tubulin Inhibitor, VERU-111, Suppresses Triple-Negative Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance.

Authors:  Shanshan Deng; Raisa I Krutilina; Qinghui Wang; Zongtao Lin; Deanna N Parke; Hilaire C Playa; Hao Chen; Duane D Miller; Tiffany N Seagroves; Wei Li
Journal:  Mol Cancer Ther       Date:  2019-10-23       Impact factor: 6.261

Review 3.  Clinically Applicable Inhibitors Impacting Genome Stability.

Authors:  Anu Prakash; Juan F Garcia-Moreno; James A L Brown; Emer Bourke
Journal:  Molecules       Date:  2018-05-13       Impact factor: 4.411

4.  Anti‑proliferative activity of epigallocatechin‑3‑gallate and silibinin on soft tissue sarcoma cells.

Authors:  Kamran Harati; Björn Behr; Christoph Wallner; Adrien Daigeler; Tobias Hirsch; Frank Jacobsen; Marcus Renner; Ali Harati; Marcus Lehnhardt; Mustafa Becerikli
Journal:  Mol Med Rep       Date:  2016-11-28       Impact factor: 2.952

5.  Engineering biosynthesis of the anticancer alkaloid noscapine in yeast.

Authors:  Yanran Li; Christina D Smolke
Journal:  Nat Commun       Date:  2016-07-05       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.